FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2211136052> ?p ?o ?g. }

• W2211136052 endingPage "e13647" @default.
• W2211136052 startingPage "e13647" @default.
• W2211136052 abstract "e13647 Background: Papulopustular rash associated with epidermal growth factor inhibitor (EGFRI) monoclonal antibodies (Mabs) showed a “wax and wane” pattern until cessation of therapy. A pharmacokinetic study suggested that rash caused by erlotinib, an EGFR tyrosine kinase inhibitor (TKI), regresses despite continuation of therapy at same dose (defined as “spontaneous regression”). To date, description of spontaneous regression of erlotinib-induced rash remains absence in the literature. The objective of this study is to document the clinical manifestations of erlotinib-induced skin rash to determine if characteristic differences occur between different classes of EGFRIs. Methods: Retrospective single-center chart reviews were conducted in patients (pts) who received erlotinib 150 mg daily for treatment of non-small cell lung cancer (NSCLC). Exclusion criteria included: medical records not available, insufficient documentation, rash at start of erlotinib or rash that appeared within three days after starting erlotinib, and non-papulopustular rash. The demographics of the patients, EGFRI treatment information, and dermatologic intervention management were examined. Results: Forteen eligible pts identifed out of 152 pts screened. Nine pts were not evaluable because erlotinib dose was modified or inadequate follow-up period. The median age for the 5 evaluable pts was 62 years, 3 females, 1 current and 4 former smokers, and ethnicity distribution included 3 Caucasian, 1 Hispanic, and 1 Asian. Four pts received monotherapy erlotinib. The documented rash regression occurred at a median time of 32 days (range = 12-35 days) with up to 24 months follow-up duration. None of the five pts received antimicrobial therapy and 4 received topical treatment for the management of skin rash. Conclusions: This review confirmed the occurrence of spontaneous regression of erlotinib-induced papulopustular rash. More data are warranted to better understand the EGFR TKI-induced skin rash and to improve rash management. Practitioners should note the potential difference between EGFRI Mabs and TKIs-induced skin rash to determine if different management approaches should be considered to avoid premature dose modifications of the EGFR TKI therapy. No significant financial relationships to disclose." @default.
• W2211136052 created "2016-06-24" @default.
• W2211136052 creator A5037164830 @default.
• W2211136052 creator A5058200142 @default.
• W2211136052 creator A5072179727 @default.
• W2211136052 creator A5073038696 @default.
• W2211136052 creator A5074876245 @default.
• W2211136052 creator A5082969884 @default.
• W2211136052 date "2010-05-20" @default.
• W2211136052 modified "2023-10-17" @default.
• W2211136052 title "Erlotinib-induced papulopustular rash: Need for new management approach?" @default.
• W2211136052 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e13647" @default.
• W2211136052 hasPublicationYear "2010" @default.
• W2211136052 type Work @default.
• W2211136052 sameAs 2211136052 @default.
• W2211136052 citedByCount "1" @default.
• W2211136052 countsByYear W22111360522013 @default.
• W2211136052 crossrefType "journal-article" @default.
• W2211136052 hasAuthorship W2211136052A5037164830 @default.
• W2211136052 hasAuthorship W2211136052A5058200142 @default.
• W2211136052 hasAuthorship W2211136052A5072179727 @default.
• W2211136052 hasAuthorship W2211136052A5073038696 @default.
• W2211136052 hasAuthorship W2211136052A5074876245 @default.
• W2211136052 hasAuthorship W2211136052A5082969884 @default.
• W2211136052 hasConcept C121608353 @default.
• W2211136052 hasConcept C126322002 @default.
• W2211136052 hasConcept C141071460 @default.
• W2211136052 hasConcept C16005928 @default.
• W2211136052 hasConcept C2777673923 @default.
• W2211136052 hasConcept C2778081122 @default.
• W2211136052 hasConcept C2778087573 @default.
• W2211136052 hasConcept C2778570526 @default.
• W2211136052 hasConcept C2778847519 @default.
• W2211136052 hasConcept C2779438470 @default.
• W2211136052 hasConcept C2909325608 @default.
• W2211136052 hasConcept C71924100 @default.
• W2211136052 hasConceptScore W2211136052C121608353 @default.
• W2211136052 hasConceptScore W2211136052C126322002 @default.
• W2211136052 hasConceptScore W2211136052C141071460 @default.
• W2211136052 hasConceptScore W2211136052C16005928 @default.
• W2211136052 hasConceptScore W2211136052C2777673923 @default.
• W2211136052 hasConceptScore W2211136052C2778081122 @default.
• W2211136052 hasConceptScore W2211136052C2778087573 @default.
• W2211136052 hasConceptScore W2211136052C2778570526 @default.
• W2211136052 hasConceptScore W2211136052C2778847519 @default.
• W2211136052 hasConceptScore W2211136052C2779438470 @default.
• W2211136052 hasConceptScore W2211136052C2909325608 @default.
• W2211136052 hasConceptScore W2211136052C71924100 @default.
• W2211136052 hasIssue "15_suppl" @default.
• W2211136052 hasLocation W22111360521 @default.
• W2211136052 hasOpenAccess W2211136052 @default.
• W2211136052 hasPrimaryLocation W22111360521 @default.
• W2211136052 hasRelatedWork W1110380345 @default.
• W2211136052 hasRelatedWork W1986001758 @default.
• W2211136052 hasRelatedWork W1997605441 @default.
• W2211136052 hasRelatedWork W2122899729 @default.
• W2211136052 hasRelatedWork W2133353215 @default.
• W2211136052 hasRelatedWork W3003805320 @default.
• W2211136052 hasRelatedWork W3034543458 @default.
• W2211136052 hasRelatedWork W4225377951 @default.
• W2211136052 hasRelatedWork W4283767488 @default.
• W2211136052 hasRelatedWork W4291944910 @default.
• W2211136052 hasVolume "28" @default.
• W2211136052 isParatext "false" @default.
• W2211136052 isRetracted "false" @default.
• W2211136052 magId "2211136052" @default.
• W2211136052 workType "article" @default.